Arnold B. Calmann (abc@saiber.com)
`Katherine A. Escanlar (kae@saiber.com)
`SAIBER LLC
`One Gateway Center, 10th Floor, Suite 1000
`Newark, New Jersey 07102
`Telephone: (973) 622-3333
`
`Douglas H. Carsten (dcarsten@wsgr.com)
`Elham Firouzi Steiner (esteiner@wsgr.com)
`Nathaniel R. Scharn (nscharn@wsgr.com)
`Alina L. Litoshyk (alitoshyk@wsgr.com)
`James P.H. Stephens (jstephens@wsgr.com)
`WILS ON SONS INI GOODRICH & ROS ATI P.C.
`12235 El Camino Real
`San Diego, California 92130
`Telephone: (858) 350-2300
`
`Attorneys for Defendant Mylan GmbH.
`
`
`IN THE UNITED STATES DISTRICT COURT
`DISTRICT OF NEW JERSEY
`
`
`
`SANOFI-AVENTIS U.S. LLC, SANOFI-
`AVENTIS DEUTSCHLAND GMBH, and
`SANOFI WINTHROP INDUSTRIE,
`
`
`
`Plaintiffs,
`
`v.
`
`MYLAN GMBH,
`
`Defendant.
`
`C.A. No. 17-cv-09105-SRC-CLW
`
`
`
`
`MYLAN GMBH’S INVALIDITY CONTENTIONS
`
`Pursuant to Local Patent Rules 3.3 and 3.6, Defendant Mylan GmbH hereby submits its
`
`Invalidity Contentions (“Invalidity Contentions”) to Plaintiffs Sanofi-Aventis U.S. LLC, Sanofi-
`
`Aventis Deutschland GmbH, and Sanofi Winthrop Industrie (collectively, “Sanofi” or
`
`“Plaintiffs”).
`
`These Invalidity Contentions are made in response to Sanofi’s Complaint (filed October
`
`24, 2017 (Dkt. No. 1)) and Disclosure of Asserted Claims (served December 26, 2017)
`
`1
`
`Sanofi Exhibit 2009.001
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`7.
`
`Obviousness Combinations
`
`Pursuant to Local Patent Rule 3.3(b), Mylan GmbH identifies the combinations of prior
`
`art included in the attached claim charts as the combinations that render the claims
`
`obvious. Many of the prior art references disclosed therein disclose or render obvious asserted
`
`claims on their own, but to the extent Sanofi contends the prior art lacks any certain limitation of
`
`the patents-in-suit, the POSA would have been motivated to combine any given primary
`
`reference with other disclosed references to arrive at the claimed invention.
`
`This case is in the early stages, with most discovery still upcoming, and the close of fact
`
`discovery is still eight months away. The Court has not construed any claims, and expert reports
`
`are not due until sometime after the Court’s claim construction order. Further, Sanofi has only
`
`recently disclosed its validity and infringement contentions, but may seek leave to amend its
`
`contentions in the future. As a result, Mylan GmbH reserves the right to supplement and/or
`
`amend these Contentions in response to positions taken by Sanofi with additional selections from
`
`the cited prior art, as well as with additional prior art references.
`
`In addition, Sanofi’s Responses to Invalidity Contentions generically deny that many
`
`limitations are present in the prior art, and do so without explanation. See, e.g., Infringement
`
`Contentions, Exhibit C at 36-37. As a result, Mylan GmbH is unable to further narrow the range
`
`of combinations that it may rely on at trial. Additional disclosure is also premature, as Mylan
`
`GmbH is not required to provide its expert report on invalidity until after claim construction. In
`
`the spirit of cooperation, however, while reserving the right to rely on any combination described
`
`in the attached claim chart for this patent, Mylan GmbH hereby identifies exemplary
`
`combinations that it may be more likely to rely on:
`
` Judson, alone or in combination with Steenfeldt-Jensen, Atterbury, Møller,
`
`Burroughs, Bechtold, Bendek, Chanoch, Frezza, Giambattista ’095, Giambattista.
`
`268
`
`Sanofi Exhibit 2009.002
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`’794, Haber ’160, Haber ’528, Harris ’895, Harris ’896, Hjertman, Horstman,
`
`Kirchhofer ’023, Kirchhofer ’224, Kovelman, Polzin, Roe, Sams ’591, Wilkens,
`
`Balkwill, Sams ’152, Haber ’609, Michel, Gabriel, Pawelka, Walters ’495,
`
`Kirchofer ’698, Bush, and Walters ’471;
`
` Steenfeldt-Jensen, alone or in combination with Judson, Atterbury, Møller,
`
`Burroughs, Bechtold, Bendek, Chanoch, Frezza, Giambattista ’095, Giambattista
`
`’794, Haber ’160, Haber ’528, Harris ’895, Harris ’896, Hjertman, Horstman,
`
`Kirchhofer ’023, Kirchhofer ’224, Kovelman, Polzin, Roe, Sams ’591, Wilkens,
`
`Balkwill, Sams ’152, Haber ’609, Michel, Gabriel, Pawelka, Walters ’495,
`
`Kirchofer ’698, Bush, and Walters ’471;
`
` Burroughs, alone or in combination with Judson, Steenfeldt-Jensen, Atterbury,
`
`Møller, Bechtold, Bendek, Chanoch, Frezza, Giambattista ’095, Giambattista
`
`’794, Haber ’160, Haber ’528, Harris ’895, Harris ’896, Hjertman, Horstman,
`
`Kirchhofer ’023, Kirchhofer ’224, Kovelman, Polzin, Roe, Sams ’591, Wilkens,
`
`Balkwill, Sams ’152, Haber ’609, Michel, Gabriel, Pawelka, Walters ’495,
`
`Kirchofer ’698, Bush, and Walters ’471;
`
` Møller, alone or in combination with Judson, Steenfeldt-Jensen, Atterbury,
`
`Burroughs, Bechtold, Bendek, Chanoch, Frezza, Giambattista ’095, Giambattista
`
`’794, Haber ’160, Haber ’528, Harris ’895, Harris ’896, Hjertman, Horst man,
`
`Kirchhofer ’023, Kirchhofer ’224, Kovelman, Polzin, Roe, and Sams ’591,
`
`Wilkens, Balkwill, Sams ’152, Haber ’609, Michel, Gabriel, Pawelka, Walters
`
`’495, Kirchofer ’698, Bush, and Walters ’471;
`
`269
`
`Sanofi Exhibit 2009.003
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`Dated: April 25, 2018
`
`SAIBER LLC
`
`By: s/ Arnold B. Calman____________
`Arnold B. Calmann (ACalmann@saiber.com)
`Katherine Escanlar (KEscanlar@saiber.com)
`One Gateway Center, Suite 1000
`Newark, New Jersey 07102
`Telephone: (973) 622-3333
`
`
`
`OF COUNSEL:
`
`WILSON SONSINI GOODRICH &
`ROSATI
`Douglas H. Carsten (dcarsten@wsgr.com)
`Elham Firouzi Steiner (esteiner@wsgr.com)
`Nathaniel R. Scharn (nscharn@wsgr.com)
`Alina L. Litoshyk (alitoshyk@wsgr.com)
`12235 El Camino Real
`San Diego, CA 92130-3002
`Phone: (858) 350-2300
`Fax: (858) 350-2399
`
`Attorneys for Defendant Mylan GmbH.
`
`
`
`
`
`634
`
`Sanofi Exhibit 2009.004
`Mylan v. Sanofi
`IPR2018-01676
`
`